The U.S. sucralfate market is estimated to be valued at US$ 296.2 million in 2017 and is expected to exhibit a CAGR of 3.1% over the forecast period of 2018–2026, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Sucralfate is a medication used to treat gastric ulcers. It forms a complex gel-like substance when it comes into contact with stomach acid, which acts as a protective barrier for healing ulcers. The key advantages of sucralfate include its ability to alleviate ulcer symptoms such as pain and discomfort and promote healing of the gastric lining.
There is a significant need for sucralfate in the market due to the high prevalence of gastric ulcers, particularly in the U.S. population. Gastric ulcers are commonly caused by factors such as Helicobacter pylori infection, non-steroidal anti-inflammatory drug (NSAI use, and stress. The demand for sucralfate is expected to grow as more individuals are diagnosed with gastric ulcers and seek effective treatment options.
Market Key Trends:
One key trend observed in the U.S. sucralfate market is the increasing preference for generic versions of the medication. Generic sucralfate offers a cost-effective alternative to branded options, making it more accessible to a larger patient population. With the rising healthcare costs and the pressure to reduce medical expenses, patients and healthcare providers are increasingly opting for generic medications like sucralfate.
For example, Pharmaceutical Associates Inc., one of the key players in the U.S. sucralfate market, offers generic sucralfate tablets that provide similar therapeutic effects as the branded version. This trend is expected to drive the market growth, as patients and healthcare systems strive to achieve cost savings without compromising on quality healthcare.
PEST Analysis:
- Political: The political landscape in the U.S. plays a crucial role in the pharmaceutical industry. Government regulations governing drug approval, pricing, and reimbursement policies can significantly impact the sucralfate market.
- Economic: The economic factors influencing the U.S. sucralfate market include healthcare expenditure, insurance coverage, and affordability of medications. The economic stability of the population determines their ability to afford sucralfate treatment.
- Social: The prevalence of gastric ulcers and awareness about their treatment options among the population are social factors affecting the sucralfate market. Lifestyle choices, such as dietary habits and stress levels, also contribute to the occurrence of gastric ulcers.
- Technological: Advancements in drug delivery systems, such as controlled-release formulations, can enhance the effectiveness and patient compliance of sucralfate. Technological innovations also impact manufacturing processes and quality control measures.
Key Takeaways:
- The U.S. Sucralfate Market Demand is expected to witness high growth, exhibiting a CAGR of 3.1% over the forecast period, due to increasing incidences of gastric ulcers.
- Regional analysis indicates that the U.S. is the fastest-growing and dominating region in the sucralfate market. The high prevalence of gastric ulcers, well-established healthcare infrastructure, and availability of various treatment options contribute to this growth.
- Key players operating in the U.S. sucralfate market include Teva Pharmaceutical Industries Ltd., Allergan plc, Vertice Pharma LLC, and Pharmaceutical Associates Inc. These companies are actively involved in product development and strategic collaborations to expand their market presence and cater to the growing demand for sucralfate.
In conclusion, the U.S. sucralfate market is expected to experience significant growth due to increasing incidences of gastric ulcers. The market is characterized by the rise in preference for generic medications, driven by the need for cost-effective treatment options. Government regulations, economic factors, social awareness, and technological advancements will continue to shape the market dynamics in the coming years.
The Global Sucralfate Market is anticipated to grow at a CAGR of 4.8% during the forecast period.
Sucralfate is the generic form of the brand-name drug, Carafate.
It is a prescription medicine used to treat ulcers of the upper gastrointestinal tract, peptic ulcer disease, and to prevent reoccurrence of ulcers.
Sucralfate is a hydroxy aluminum salt of sucrose octasulfate that functions as a local mucosal adherent.
It forms a coating over ulcers by sticking to the affected area, which protects the area from acid and enzymes and helps ulcers to heal more quickly.Sucralfate is a hydroxy aluminum salt of sucrose octasulfate that functions as a local mucosal adherent.
Sucralfate can also be used in treating ulcers and upper gastrointestinal disorders of dog, horse, and cat, which may arise due to drugs (particularly non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids), toxic chemical ingestion, liver disease, renal failure, carcinoma, stress (trauma, shock, sepsis, and burns), and inflammatory bowel disease.Get Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-61559?utm_source=OP/SKThe factors that propel the growth of the Sucralfate Market include increasing demand, rapid urbanization & industrialization, and product development & technological innovations.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.
Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.
Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.
Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.
